Effect of Prophylactically Applied CpG ODN on the Development of Myocarditis in Mice Infected with Coxsackievirus B3

Tiesuo Zhao,Xiuli Wu,Dandan Song,Mingli Fang,Sheng Guo,Peiyin Zhang,Liying Wang,Liping Wang,Yongli Yu
DOI: https://doi.org/10.1016/j.intimp.2012.09.018
IF: 5.714
2012-01-01
International Immunopharmacology
Abstract:Coxsackievirus B3 was one of the major pathogens causing viral myocarditis. Toll-like receptor 9 activation contributed to the innate immune response in the process of CVB3-induced myocarditis. In order to find out how CpG oligodeoxynucleotide, known as a TLR-9 agonist, would affect the CVB3-induced myocarditis, we chose a C-type CpG oligodeoxynucleotide (YW002) injected to the mice one day before CVB3 challenge. On day 4 post CVB3 infection, 3 mice in each group were randomly sacrificed and their hearts were isolated to detect CVB3 replication. On day 10, the CVB3 neutralizing antibody and inflammatory change of the hearts were detected. The results indicated that the CVB3-induced myocarditis was aggravated with the declining body weight of mice, decreasing neutralizing antibody, and uncontrolling virus replication by injecting 20 μg YW002 per mouse. When adjusted the amount at 10 μg YW002 per mouse, there were no signs of aggravation in myocarditis. Plus, the mortality of the infected mice was reduced, the neutralizing antibody level was raised and the replication of virus was restrained. These results suggested that a proper amount of CpG oligodeoxynucleotide application could help to inhibit CVB3 infection.
What problem does this paper attempt to address?